PDF

The federal confidentiality protections for substance use disorder (SUD) treatment records under 42 CFR Part 2 generally require a patient’s written consent to share information. Providers often have questions about how to fill out a consent form that authorizes disclosures to multiple parties in a way that complies with Part 2 and the HIPAA Privacy Rule.

During the COVID-19 public health emergency (PHE) the U.S. Department of Health and Human Services’ (HHS) Office for Civil Rights (OCR) sought to increase patient access to telehealth services by waiving penalties for violations of certain requirements under HIPAA. OCR also provided flexibility for sharing patient identifying protected heath information (PHI) for public health purposes. With the end of PHE, these measures have expired.

During the COVID-19 public health emergency (PHE) the U.S. Department of Health and Human Services’ (HHS) Office for Civil Rights (OCR) sought to increase access to treatment by issuing guidance on the use of remote communication technologies, including audio-only technology (e.g.,Voice over Internet Protocol (VoIP) and mobile technologies that use electronic media such as the internet, intra-and extranets, cellular, and Wi-Fi), to provide telehealth2 in compliance with HIPAA. While the PHE ended on May 11, 2023, OCR’s guidance on the use of audio-only technology for telehealth remains in effect.

This resource describes key privacy considerations for patients’ SUD treatment records that originate from a Part 2 program or provider within a CMHC.

The federal health privacy laws and regulations for SUD and MH treatment have recently changed, and more changes are forthcoming. This resource provides information about the changes and links to resources where you can learn more.

CoE-PHI resource that describes the Information Blocking Rule and explains that it does not preempt stricter privacy laws and regulations such as 42 CFR Part 2.